Takano H, Taenaka Y, Nakatani T, Noda H, Kinoshita M, Matsuda T, Akutsu T, Manabe H
Nihon Kyobu Geka Gakkai Zasshi. 1989 Oct;37(10):2072-81.
One of the most important characteristics of a ventricular assist device (VAD) is good antithrombogenicity such that the circulating blood does not clot on the surface even when the bypass flow through the device is reduced at the time of weaning-off. A pneumatic and diaphragm-type VAD with excellent antithrombogenicity was developed for clinical use. The pump is made of Japanese-made segmented polyether polyurethane and the maximum output is 7.0 L/min. If the bypass flow was maintained above 2.0 L/min during early postoperative period, thrombus formation was rarely observed even when the flow rate decreased afterwards in chronic animal experiments using 30 goats. Experimental analyses suggested that a biolization mechanism of the material surface covered by absorbed plasma protein might play a major role in the establishment of antithrombogenicity of the pump. No mechanical failure, thrombosis, calcification, and complication in experimental animals occurred when the VAD manufactured under our good quality control system was driven adequately. These results proved that the VAD could be used reliably for at least 3 months. In conclusion, the VAD is safely applicable to clinical cases and contributes to treatments of profound heart failure patients.
心室辅助装置（VAD）最重要的特性之一是具有良好的抗血栓形成性，即便是在撤机时流经该装置的旁路血流减少，循环血液也不会在其表面凝结。一种具有优异抗血栓形成性的气动隔膜式VAD被研发用于临床。该泵由日本制造的分段聚醚聚氨酯制成，最大输出量为7.0升/分钟。在使用30只山羊的慢性动物实验中，若术后早期旁路血流维持在2.0升/分钟以上，即便之后流速降低，血栓形成也很少见。实验分析表明，被吸附的血浆蛋白覆盖的材料表面的生物化机制可能在泵的抗血栓形成性确立中起主要作用。当在我们良好的质量控制体系下制造的VAD得到充分驱动时，实验动物未出现机械故障、血栓形成、钙化及并发症。这些结果证明该VAD可可靠使用至少3个月。总之，该VAD可安全应用于临床病例，并有助于治疗重度心力衰竭患者。
